A New Era of Myasthenia Gravis Treatment
Episode 77, Nov 18, 2022, 11:00 AM
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with George Small, MD, an adult neurologist at Allegheny Health Network, who discussed the state of care for myasthenia gravis and its recent success, the corresponding changes to patient care, and the current era of treatment that the field has entered, among other topics.
Looking for more myasthenia gravis discussion? Check out this NeurologyLive® Peers & Perspectives series, featuring James F. Howard Jr., MD, and Nicholas J. Silvestri MD, FAAN: Updates in the Management of Myasthenia Gravis Peers and Perspectives
Episode Breakdown:
In this episode, we spoke with George Small, MD, an adult neurologist at Allegheny Health Network, who discussed the state of care for myasthenia gravis and its recent success, the corresponding changes to patient care, and the current era of treatment that the field has entered, among other topics.
Looking for more myasthenia gravis discussion? Check out this NeurologyLive® Peers & Perspectives series, featuring James F. Howard Jr., MD, and Nicholas J. Silvestri MD, FAAN: Updates in the Management of Myasthenia Gravis Peers and Perspectives
Episode Breakdown:
- 1:15 – The perspective on the current state of care in myasthenia gravis
- 4:05 – The rapidly evolving treatment landscape
- 6:40 – Allegheny Health Network's approach to myasthenia gravis care
- 10:05 – Treatment selection among patient groups
- 15:45 – Neurology News Minute
- 18:45 – Current challenges and adjustments with treatments
- 21:20 – Nonpharmacologic approaches to myasthenia gravis
- 26:55 – Challenges for patients and education around treatment access
- 28:35 – The future of myasthenia gravis care
This episode is brought to you by the Medical World News streaming service. Check out new content and shows every day, only at medicalworldnews.com
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
- Neurosteer Single-Channel EEG Platform Cleared by FDA
- Neurocrine Biosciences Submits Supplemental NDA for Valbenazine in the Treatment of Huntington Disease Chorea
- FDA Refuses to File BrainStorm’s BLA for NurOwn Mesenchymal ALS Therapy
- FDA Accepts NDA for Parkinson Disease Treatment IPX203
- FDA Accepts NDA for Myasthenia Gravis Treatment Zilucoplan
Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.